Nominations are currently being accepted for the Charles River Laboratories Excellence in Refinement Award, sponsored by Charles River’s Commitment to Humane Animal Research Through Excellence and Responsibility (CHARTER) Program in cooperation with the Johns Hopkins Center for Alternatives to Animal Testing (CAAT). This award honors an individual who has made outstanding contributions to the development, promotion and/or implementation of refinement alternatives.
Charles River possesses strong analytical capabilities to thoroughly assess the physicochemical properties of complex proteins, which allows for the development of robust product formulations.
We are committed to providing testing and regulatory support to companies developing biosimilar products. Recently published articles highlight our insights and key considerations for biosimilar companies.
When pressure comes to increase efficiency, you may turn to insourcing, outsourcing or a mix of both. Keeping visibility of your testing programs, however, is still important. RightSource℠ helps you find balance between these options to reduce costs, retain visibility and focus on your core competencies.
Dr. Scott Fountain joined our team as executive director of North American laboratory sciences and clinical support for safety assessment. He will ensure the quality and alignment of laboratory sciences across Charles River.
Charles River entered a collaboration with Quintiles and City of Hope, with funding from the California Institute for Regenerative Medicine (CIRM), to establish the Translating Center in San Diego, CA, which offers end-to-end nonclinical, clinical and manufacturing services for stem-cell-based projects.
In several poster presentations, Charles River demonstrated how new immune checkpoint inhibitor data enhances our humanized oncology models, and provided a detailed overview of our current PDX models.
This video presentation of our poster, presented at Neuroscience 2016, outlines how touchscreen testing and MR spectroscopy were used to detect reduced cognition and altered brain metabolites in the CVN mouse model of Alzheimer's disease.
Charles River now offers comprehensive model creation services utilizing CRISPR/Cas9 and custom RNAi technology.
With the 2018 deadline quickly approaching to achieve full registration of your manufactured substance, let the scientific experts at Charles River ensure your REACH requirements are met in a complete and timely manner.